cysteine and Congenital Thrombotic Thrombocytopenic Purpura

cysteine has been researched along with Congenital Thrombotic Thrombocytopenic Purpura in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Coppo, P; Curie, A; De Meyer, SF; De Waele, L; Joly, BS; Kangro, K; Kaplanski, G; Männik, A; Roose, E; Tellier, E; Tersteeg, C; Vanhoorelbeke, K; Veyradier, A1
Ercig, B; Nicolaes, GAF; Reutelingsperger, CPM; Vanhoorelbeke, K; Voorberg, J; Wichapong, K1
Fujimura, Y; Ishizashi, H; Kokame, K; Maeda, H; Matsumoto, M; Miyata, T; Nakagaki, T; Nozaki, C; Soejima, K; Yagi, H1
Bouhassira, EE; Dong, L; Ginsburg, D; Tsai, HM; Zhou, W1
Bowen, DJ; Collins, PW1

Reviews

2 review(s) available for cysteine and Congenital Thrombotic Thrombocytopenic Purpura

ArticleYear
Insights into 3D Structure of ADAMTS13: A Stepping Stone towards Novel Therapeutic Treatment of Thrombotic Thrombocytopenic Purpura.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:1

    Topics: ADAMTS13 Protein; Animals; Autoantibodies; Autoimmune Diseases; Computational Biology; Crystallography, X-Ray; Cysteine; Disease Models, Animal; Humans; Imaging, Three-Dimensional; Mutation; Peptides; Protein Conformation; Protein Domains; Purpura, Thrombotic Thrombocytopenic; Rituximab; Structure-Activity Relationship; Thrombospondins; von Willebrand Factor

2018
Insights into von Willebrand factor proteolysis: clinical implications.
    British journal of haematology, 2006, Volume: 133, Issue:5

    Topics: ABO Blood-Group System; ADAM Proteins; ADAMTS13 Protein; Amino Acids; Cysteine; Humans; Hydrolysis; Ligands; Models, Biological; Mutation; Polymorphism, Genetic; Purpura, Thrombotic Thrombocytopenic; Tyrosine; von Willebrand Diseases; von Willebrand Factor

2006

Other Studies

3 other study(ies) available for cysteine and Congenital Thrombotic Thrombocytopenic Purpura

ArticleYear
Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP.
    Blood advances, 2021, 11-09, Volume: 5, Issue:21

    Topics: ADAMTS13 Protein; Autoantibodies; Cysteine; Humans; Immunoglobulin G; Purpura, Thrombocytopenic, Idiopathic; Purpura, Thrombotic Thrombocytopenic

2021
ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.
    Blood, 2003, Nov-01, Volume: 102, Issue:9

    Topics: ADAM Proteins; ADAMTS13 Protein; Autoantibodies; Cysteine; Epitope Mapping; Humans; Immunoglobulin G; Metalloendopeptidases; Mutagenesis, Site-Directed; Mutation; Protein Structure, Tertiary; Purpura, Thrombotic Thrombocytopenic; von Willebrand Factor

2003
Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?
    The Journal of biological chemistry, 2005, Dec-02, Volume: 280, Issue:48

    Topics: ADAM Proteins; ADAMTS13 Protein; Animals; Autoantibodies; Blood Platelets; Chlorocebus aethiops; COS Cells; Cysteine; DNA Primers; Humans; Immunoglobulin G; Immunoprecipitation; Plasmids; Protein Binding; Protein Structure, Tertiary; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Temperature; Time Factors; von Willebrand Factor

2005